Guideline for the diagnosis and management of hyperuricemia and gout in China(2019)
中国高尿酸血症与痛风诊疗指南(2019)(43278)
The ACE trial: a new perspective on the effect of acarbose on cardiovascular outcomes
ACE研究：阿卡波糖对心血管结局影响的新视角(33723)
Implications and challenges of the ACE trial
ACE研究的启示和挑战(30276)
Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南(27342)
Value of individualized, patient-centered use of short-acting glucagon-like peptide-1 receptor agonist lixisenatide for the treatment of type 2 diabetes mellitus
短效胰升糖素样肽1受体激动剂利司那肽在2型糖尿病个体化治疗中的价值(26191)
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
利司那肽在2型糖尿病个体化治疗中的应用(25655)
The author, at the point of submission, must notify any potential conflict of interest, whether it is financial interest or other forms of conflicts of interest.
Relevant interests to be reported including but not limited to the following, if they are related with the topic of the submitted manuscript: current or in the past 2 years, the author is (was) employed by, or consults or has consulted for, or received lecture fees from companies which manufacture the products or provide services related to the subject matter in the manuscript. Other pertinent issues, such as ownership interest, membership, advisory committees should also be mentioned.
The corresponding author is responsible for reading and summarizing the Conflict of Interest disclosure on behalf of all authors.
